Skip to content

Study · In vitro (cells) · 2013

1 result

[Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)].

Dzhokhadze TA, Buadze TZh, Gaĭozishvili MN, Rogava MA, Lazhava TA

Georgian medical news1 Dec 2013Cited by 1 (Europe PMC)

PMID24423684 (opens in a new tab)PepBankPUB-24423684
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In lymphocyte cultures from patients with hypertrophic cardiomyopathy and their relatives, epithalon lowered the level of chromosomal instability, and it was the most effective of the tested bioregulators.

    In plain wordsIn lab cells from donors with hypertrophic cardiomyopathy and their relatives, epithalon lowered chromosome instability more than the other tested peptides.

    Peptide
    Epitalon
    Outcome
    DecreaseChromosomal instability with epithalon
    Study

    humann: not reported in source

    Lymphocyte cultures from patients with hypertrophic cardiomyopathy and relatives
    Outcome group
    Genome stability · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The most effective protective action in relation normalization of functional parameters of the genome shows Epithalon for lowering the level of chromosomal instability in patients with hypertrophic cardiomyopathy and relatives of patients with HCM.
    1 context sentence
    Summary · context
    Studies conducted both in intact cultures and cultures exposed to the influence of peptide - bioregulators Epithalon, Vilon and Livagen.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 5 to 11Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 7 times, first on 21 Oct 2026, 17:05 UTC. The status did not change between them.

    Study results updated

  2. Versions 3 to 4

    21 Oct 2026, 16:35 UTC

    The same notice was added 2 times, first on 21 Oct 2026, 16:35 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 17:28 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.